In a meta-analysis of several studies using various methodologies, worldwide prevalence of NAFLD (Non-alcoholic fatty liver disease) is 25.2% and 6.45% for NASH (Non-Alcoholic SteatoHepatitis). A growing number of patients progress to end-stage liver disease, yet the condition is still poorly understood and there is no known treatment. The need for therapeutic agents is urgent. At Cerba Research, we are committed to improving the diagnosis and treatment of NASH.
In 2016, after we successfully supported their Phase II NASH study, a midsize biotech engaged our services for a Phase III registration trial. Gratified to have gained their trust and eager to continue our productive collaboration with this meticulous client, we rolled up our sleeves and took on the challenge of supporting the largest NASH Phase III study to date.
Discover how our experts supported the largest global Phase III NASH study to date.
Lab Support for the Largest Global Phase III NASH Study to Date
Reach out to our experts and discover how we can help you advance your clinical trialContact Us